HERON THERAPEUTICS, INC. /DE/ HRTX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, HERON THERAPEUTICS, INC. /DE/ reported revenue across 4 products and services; the largest, CINVANTI, was $96.8M, 62.5% of the filed sum (-3.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- CINVANTI$96.8M62.5%-3.3% yoy
- ZYNRELEF$38.1M24.6%+49.0% yoy
- Aponvie$11.6M7.5%+156.1% yoy
- SUSTOL$8.5M5.5%-39.9% yoy
Members sum to the consolidated $155M for this period.
- CINVANTI$20.5M59.2%-20.2% yoy
- ZYNRELEF$10.2M29.5%+27.3% yoy
- Aponvie$3.39M9.8%+50.2% yoy
- SUSTOL$547K1.6%-80.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.